IN THE CLAIMS

Original Claims 1-66 were previously canceled.

Claims 67-136 are pending in this Application.

Claims 67-104 and 113-120 are currently amended.

Claims 105-112 and 121-122 are canceled.

Claims 123-136 were previously presented.

Claims 137-154 are new.

67. **(currently amended)** A compound ~~for modulating tyrosine kinase activity~~ of Formula **I**,



I

or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof, wherein,

R^1 is C_1-C_3 alkyl optionally substituted with between one and three R^{50} substituents;

R^2 is selected from halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(=O)R^3$, $-N(R^3)CO_2R^4$, $-C(=O)R^3$, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ lower alkenyl, and ~~optionally substituted lower~~ alkynyl;

R^3 is -H or R^4;

R^4 is selected from ~~optionally substituted~~ lower alkyl; lower alkyl substituted with one, two, or three halogen; ~~optionally substituted~~ aryl; aryl substituted with one, two, or three halogen; ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ heterocyclyl, and ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ a five- to seven-membered heterocyclyl~~, said optionally substituted five- to seven-membered heterocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

q is 0, 1, 2, 3, 4, or 5;

Z is selected from $-OCH_2-$, -O-, $-S(O)_{0-2}-$, $-N(R^5)CH_2-$, and $-NR^5-$;

R^5 is -H or ~~optionally substituted~~ lower alkyl;

R^{50} is -H, halo, trihalomethyl, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(=O)N(R^3)R^4$, $-C(=NR^{25})N(R^3)R^4$, $-C(=NR^{25})R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(=O)R^3$, ~~optionally substituted~~ alkoxy, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ aryl, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ heterocyclyl, and ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl; or

two of R^{50}, when taken together on the same carbon are oxo; or

two of R^{50}, when taken together with a common carbon to which they are attached, form a ~~optionally substituted~~ three- to seven-membered spirocyclyl~~, said optionally substituted three- to seven-membered spirocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P;

R^{25} is selected from -H, -CN, $-NO_2$, $-OR^3$, $-S(O)_{0-2}R^4$, $-CO_2R^3$, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ lower alkenyl, and ~~optionally substituted~~ lower alkynyl;

M^1-M^2-M^3-M^4- together are according to formula **II**:



II

wherein X^1, X^2, and optionally X^3, represent the atoms of a saturated bridged ring system, said saturated bridged ring system containing up to three annular heteroatoms represented by any of X^1, X^2, and X^3; wherein,

each X^1 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

each X^2 is independently a bridgehead methine optionally substituted with R^6, or a bridgehead nitrogen;

each X^3 is independently selected from $-C(R^6)R^7-$, -O-, $-S(O)_{0-2}-$, and $-NR^8-$;

provided, for X^1, X^2, and X^3, there are no nitrogen-nitrogen annular bonds nor geminal di-nitrogen substitutions;

E is selected from $-NR^9-$, -O-, and absent;

Y is either:

a C_{1-3} alkylene linker, between the oxygen at the 7-position of the quinazoline ring system of **I** and either E, or when E is absent, any ring atom of the saturated bridged ring system except X^2, when X^2 is a bridgehead nitrogen; provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of **I** and either E, or when E is absent, any heteroatom represented by X^1, X^2 or X^3; or

Y is absent, when Y is absent, E is also absent; said saturated bridged ring system is directly attached to the oxygen at the 7-position of the quinazoline ring system of **I** via a carbon atom of said saturated bridged ring system;

m and p are each independently ~~from one to four~~ 1, 2, 3, or 4;

n is ~~from zero to two~~ 0, 1, or 2, when n is zero, then there is a direct single bond between the two bridgehead X^2's;

R^6 and R^7 are each independently selected from -H, halogen, trihalomethyl, -CN, $-NH_2$, $-NO_2$, $-OR^3$, $-N(R^3)R^4$, $-S(O)_{0-2}R^4$, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-N(R^3)SO_2R^4$, $-N(R^3)C(O)R^3$, $-NCO_2R^3$, $-C(O)R^3$, ~~optionally substituted~~ lower alkyl, ~~optionally substituted~~ aryl, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ heterocyclyl, ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl; or

R^6 and R^7, when taken together are oxo; or

R^6 and R^7, when taken together with a common carbon to which they are attached, form a ~~optionally substituted~~ three- to seven-membered spirocyclyl~~, said optionally substituted three- to seven-membered spirocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P; and

R^8 is selected from R^3, $-SO_2N(R^3)R^4$, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$;

R^9 is -H or ~~optionally substituted~~ lower alkyl;

with the proviso that when Y is a C_{1-3} alkylene linker, E is absent, Z is -NH- or $-N(CH_3)-$, R^1 is a C_{1-3} alkyl, R^2 is -H or halogen, n = 0, and the atoms X^1 of one bridge of the saturated bridged ring system, when combined with both bridgehead atoms, X^2, of the saturated bridged ring system, represent:

either a pyrrolidine ring or a piperidine ring, and any atom, X^1 or X^2, of either of said pyrrolidine ring or said piperidine ring is attached to Y; then the other bridge of said saturated bridged ring system cannot be any one of $-OC(O)CH_2-$, $-CH_2OC(O)-$, $-OC(O)CH_2CH_2-$, $-CH_2OC(O)CH_2-$, $-CH_2CH_2OC(O)-$, $-OC(O)CH_2NH-$, $-OC(O)CH_2N(C_{1-4}alkyl)-$, and $-OC(O)CH_2O-$;[[or]] and

either a piperazine ring or a 4-(C_{1-4} alkyl)-piperazine ring, and any atom, X^1 or X^2, of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 2- and the 3-position of either of said piperazine ring or said 4-(C_{1-4} alkyl)-piperazine ring, cannot be one of $-CH_2OC(O)CH_2-$, $-CH_2CH_2OC(O)-$, and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2}alkyl groups;[[or]] and

a piperazine ring, and any atom, X^1 or X^2, of said piperazine ring is attached to Y; then the other bridge of said saturated bridged ring system, only when attached via the 3- and the 4-position of said piperazine ring, cannot

be one of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ (and only when either of $-C(O)OCH_2CH_2-$ or $-CH_2OC(O)CH_2-$ is attached to the 3-position of said piperazine ring via their left-hand end as depicted above), and either of the two aforementioned bridges cannot be optionally substituted by one or two C_{1-2} alkyl groups~~, and~~;[[or]] and

a 2-oxomorpholine ring, said 2-oxomorpholine ring attached to Y via its 4-position; then the other bridge of said saturated bridged ring system, only when attached via the 5- and the 6-position of said 2-oxomorpholine ring, cannot be one of $-(CH_2)_g-$, $-CH_2WCH_2-$, $-CH_2WCH_2CH_2-$, and $-CH_2CH_2WCH_2-$, wherein W is -O-, $-S(O)_{0-2}-$, -NH-, or $-N(C_{1-4}$ alkyl)- and wherein g is 2, 3, or 4.

68. **(currently amended)** The compound according to claim 67, wherein Z is $-NR^5-$; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

69. **(currently amended)** The compound according to claim 68, wherein R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, and ~~optionally substituted~~ lower alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

70. **(currently amended)** The compound according to claim 69, wherein R^1 is an unsubstituted C_{1-3} alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

71. **(currently amended)** The compound according to claim 70, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], [3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and [2.2.1]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

72. **(currently amended)** The compound according to claim 71, wherein Y is selected from $-CH_2CH_2-$, $-CH_2-$, and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

73. **(currently amended)** The compound according to claim 72, wherein q is 1, 2, or 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

74. **(currently amended)** The compound according to claim 73, wherein R^5 is -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

75. **(currently amended)** The compound according to claim 74, wherein R^1 is methyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

76. **(currently amended)** The compound according to claim 75, wherein the saturated bridged ring system has a geometry selected from the group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0], and [3.1.0]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

77. **(currently amended)** The compound according to claim 76, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from $-NR^8-$, when X^1, and a bridgehead nitrogen, when X^2; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

78. **(currently amended)** The compound according to claim 77, wherein E is absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

79. **(currently amended)** The compound according to claim 78, wherein said saturated bridged ring system is according to formula **III**;



III

wherein A is selected from -O-, -$S(O)_{0-2}$-, -NR^8-, and absent; and e is 0 or 1; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

80. **(currently amended)** The compound according to claim 79, wherein Y is -CH_2-; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

81. **(currently amended)** The compound according to claim 80, wherein A is selected from -NR^8-, wherein R^8 is selected from -H, ~~optionally substituted~~ lower alkyl, -CO_2R^3, -$C(O)N(R^3)R^4$, -SO_2R^4, and -$C(O)R^3$; -O-; and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

82. **(currently amended)** The compound according to claim 81, wherein



of **I** is selected from:



and



, wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

83. **(currently amended)** The compound according to claim 82, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate,

enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

84. **(currently amended)** The compound according to claim 77, wherein said saturated bridged ring system is according to either formula **V** or formula **VI**;



V



VI

wherein R^8 is selected from -H, ~~optionally substituted~~ lower alkyl, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

85. **(currently amended)** The compound according to claim 84, wherein Y is either $-CH_2-$ or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

86. **(currently amended)** The compound according to claim 85, wherein



of **I** is selected from:



and



, wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

87. **(currently amended)** The compound according to claim 86, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

88. **(currently amended)** The compound according to claim 87, wherein R^8 is methyl or ethyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

89. **(currently amended)** The compound according to claim 78, wherein said saturated bridged ring system is according to formula **VII**;



VII

wherein A is selected from -O-, $-S(O)_{0-2}-$, $-NR^8-$, $-CR^6R^7-$, and absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

90. **(currently amended)** The compound according to claim 89, wherein R^3 is selected from -H and ~~optionally substituted~~ alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

91. **(currently amended)** The compound according to claim 90 wherein A is either $-C(R^6)R^7-$ or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

92. **(currently amended)** The compound according to claim 91, wherein A is either $-CH_2-$ or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

93. **(currently amended)** The compound according to claim 92, wherein Y is $-CH_2-$; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

94. **(currently amended)** The compound according to claim 93, wherein q is 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

95. **(currently amended)** The compound according to claim 94, wherein



of **I** is selected from:



and



, wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

96. **(currently amended)** The compound according to claim 95, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

97. **(currently amended)** The compound according to claim 75, wherein the saturated bridged ring system has a geometry selected from the group consisting of [3.3.1], [3.2.1], and [2.2.1]; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

98. **(currently amended)** The compound according to claim 97, wherein said saturated bridged ring system contains one or two annular nitrogens, said one or two annular nitrogens are selected from $-NR^8-$, when X^1, and a bridgehead nitrogen, when X^2; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

99. **(currently amended)** The compound according to claim 98, wherein said saturated bridged ring system is according to formula **VIII** or formula **IX**;



VIII



IX

wherein R^8 is selected from -H, ~~optionally substituted~~ lower alkyl, $-CO_2R^3$, $-C(O)N(R^3)R^4$, $-SO_2R^4$, and $-C(O)R^3$; and R^{26} is C_{1-3} alkyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

100. **(currently amended)** The compound according to claim 99, wherein Y is $-CH_2CH_2-$; and E is either absent or $-N(R^9)-$; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

101. **(currently amended)** The compound according to claim 100, wherein q is 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

102. **(currently amended)** The compound according to claim 101, wherein



of **I** is selected from:



and



, wherein R^{2a}, R^{2b}, and R^{2c} are each independently selected from F, Cl, and Br; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

103. **(currently amended)** The compound according to claim 102, wherein R^{2a} is F, R^{2b} is Cl, and R^{2c} is either Cl or Br; or a single geometric isomer, stereoisomer, racemate,

enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

104. **(currently amended)** The compound according to claim 103, wherein R^8 is methyl or ethyl; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

Claims 105-112 (canceled)

113. **(currently amended)** A compound ~~for modulating tyrosine kinase activity~~ of Formula Ia,



Ia

or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof, wherein,

q is 1, 2, or 3;

R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, ~~optionally substituted~~ lower alkyl, and piperazinyl substituted with methyl;

~~Y is selected from $-CH_2CH_2-$, $-CH_2-$, and absent;~~

Y is either:

$-CH_2-$ or $-CH_2CH_2-$ provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of **Ia** and E when E is $-NR^9-$ or -O-; or

Y is absent; and when Y is absent, E is also absent;

E is selected from $-NR^9-$, -O-, and absent;

R^3 is -H or R^4;

R^4 is selected from ~~optionally substituted~~ lower alkyl; lower alkyl substituted with one, two, or three halogen; ~~optionally substituted~~ aryl; aryl substituted with one, two,

or three halogen; ~~optionally substituted~~ unsubstituted lower arylalkyl; ~~optionally substituted~~ heterocyclyl; and ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ a five- to seven-membered heterocyclyl~~, said optionally substituted five- to seven-membered heterocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

R^9 is -H or ~~optionally substituted~~ lower alkyl;

R^{10} is selected from -H, ~~optionally substituted~~ alkyl, and $-OR^{13}$; and R^{11} and R^{12} are each independently selected from -H, $-CF_3$, -F, $-N(R^3)R^4$, $-N(C=O)R^3$, $-N(R^3)SO_2R^3$, $-S(O)_{0-2}R^{13}$, $-OR^{13}$, ~~$-OS(O)_{0-2}R^{13a}$~~; $-OS(O)_2$alkyl, $-NH_2$, and alkyl substituted with alkoxy; or

R^{10} is selected from -H, and $-OR^{13}$; and R^{11} and R^{12}, when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl ~~which three- to seven-membered spirocyclyl is optionally substituted with alkyl and which optionally contains one or two oxygen atoms~~; and

R^{13} is selected from -H, $-C(=O)R^4$, ~~optionally substituted~~ lower alkynyl, ~~optionally substituted~~ unsubstituted lower arylalkynyl, ~~optionally substituted~~ lower heterocyclylalkynyl, ~~optionally substituted~~ lower alkenyl, ~~optionally substituted~~ unsubstituted lower arylalkenyl, ~~optionally substituted~~ lower heterocyclylalkenyl optionally substituted with one alkyl, ~~optionally substituted~~ lower alkyl, lower alkyl substituted with one, two, or three halogen, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ aryl, ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl, and ~~optionally substituted~~ heterocyclyl; or

two R^{13}'s, when taken together, form 1) a corresponding spirocyclic ketal from R^{11}, R^{12} and the carbon to which they are attached, when R^{11} and R^{12} are both $-OR^{13}$, or 2) a corresponding cyclic ketal from R^{10} and one of R^{11} and R^{12}, and the

corresponding carbons to which they are attached, when R^{10} is $-OR^{13}$, and at least one of R^{11} and R^{12} is also $-OR^{13}$, and which spirocyclic and cyclic ketal ~~is~~ are indpendently optionally substituted with one or two alkyl~~; and~~

~~R^{13a} is alkyl~~.

114. **(currently amended)** The Compound of Claim 113 wherein

q is 1, 2, or 3;

R^2 is selected from halogen, trihalomethyl, -CN, $-NO_2$, $-OR^3$, and ~~optionally substituted~~ lower alkyl;

~~Y is selected from $-CH_2CH_2-$, $-CH_2-$, and absent;~~

Y is either:

$-CH_2-$ or $-CH_2CH_2-$ provided there are at least two carbon atoms between the oxygen at the 7-position of the quinazoline ring system of **Ia** and E when E is $-NR^9-$ or -O-; or

Y is absent; and when Y is absent, E is also absent;

E is selected from $-NR^9-$, -O-, and absent;

R^3 is -H or R^4;

R^4 is selected from ~~optionally substituted~~ lower alkyl, lower alkyl substituted with one, two, or three halogen, ~~optionally substituted~~ aryl, aryl substituted with one, two, or three halogen, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ heterocyclyl, and ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl; or

R^3 and R^4, when taken together with a common nitrogen to which they are attached, form ~~an optionally substituted~~ a five- to seven-membered heterocyclyl~~, said optionally substituted five- to seven-membered heterocyclyl~~ optionally containing at least one additional heteroatom selected from N, O, S, and P where the five- to seven-membered heterocyclyl is optionally substituted by one, two, or three alkyl;

R^9 is -H or ~~optionally substituted~~ lower alkyl;

R^{10} is selected from -H, ~~optionally substituted~~ alkyl, and $-OR^{13}$; and R^{11} and R^{12} are each independently selected from -H, $-CF_3$, -F, $-N(R^3)R^4$, $-N(C=O)R^3$, $-N(R^3)SO_2R^3$, $-S(O)_{0-2}R^{13}$, and $-OR^{13}$; or

R^{10} is selected from -H, and $-OR^{13}$; and R^{11} and R^{12}, when taken together, are oxo, exo-alkenyl, or when taken together with the carbon to which they are attached, form a three- to seven-membered spirocyclyl; and

R^{13} is selected from -H, $-C(=O)R^4$, ~~optionally substituted~~ lower alkynyl, ~~optionally substituted~~ unsubstituted lower arylalkynyl, ~~optionally substituted~~ lower heterocyclylalkynyl optionally substituted with one alkyl, ~~optionally substituted~~ lower alkenyl, ~~optionally substituted~~ unsubstituted lower arylalkenyl, ~~optionally substituted~~ lower heterocyclylalkenyl optionally substituted with one alkyl, ~~optionally substituted~~ lower alkyl, lower alkyl substituted with one, two, or three halogen, ~~optionally substituted~~ unsubstituted lower arylalkyl, ~~optionally substituted~~ aryl, ~~optionally substituted~~ lower heterocyclylalkyl optionally substituted with one alkyl, and ~~optionally substituted~~ heterocyclyl; or

two R^{13}'s, when taken together, form 1) a corresponding spirocyclic ketal from R^{11}, R^{12} and the carbon to which they are attached, when R^{11} and R^{12} are both $-OR^{13}$, or 2) a corresponding cyclic ketal from R^{10} and one of R^{11} and R^{12}, and the corresponding carbons to which they are attached, when R^{10} is $-OR^{13}$, and at least one of R^{11} and R^{12} is also $-OR^{13}$; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

115. **(currently amended)** The compound according to claim 114, wherein Y is either $-CH_2-$ or absent; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

116. **(currently amended)** The compound according to claim 115, wherein one of R^{11} and R^{12} is $-OR^{13}$, wherein R^{13} is selected from -H, $-C(O)R^4$, ~~and optionally substituted~~ lower alkyl, and lower alkyl substituted with one, two, or three halogen; and R^{10} and the other of R^{11} and R^{12} are both -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

117. **(currently amended)** The compound according to claim 115, wherein one of R^{11} and R^{12} is -F; and R^{10} and the other of R^{11} and R^{12} are both -H; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

118. **(currently amended)** The compound according to claim 115, wherein R^{13} is an alkyl group containing at least one fluorine substitution thereon; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

119. **(currently amended)** The compound according to claim 115, wherein q is 2 or 3; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

120. **(currently amended)** The compound according to claim 119, wherein each R^2 is independently selected from -F, -Cl, -Br, $-CF_3$, $-CH_3$, and $-OR^{25}$; wherein R^{25} is either methyl or aryl, each optionally substituted with one to three halogens; or a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof. **Claims 121-122 (canceled)**

123. **(previously presented)** A compound selected from 1,4:3,6-dianhydro-2-*O*-[4-(methyloxy)carbonyl-2-(methyloxy)phenyl]-5-*O*-(methylsulfonyl)-D-glucitol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-O-{2-(methyloxy)-4-[(methyloxy)carbonyl]phenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{2-(methyloxy)-4-[(methyloxy)carbonyl]-5-nitrophenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{5-amino-2-(methyloxy)-4-[(methyloxy)carbonyl]-phenyl}-L-iditol; 1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[6-(methyloxy)-4-oxo-3,4-dihydroquinazolin-7-yl]-L-iditol; and 1,4:3,6-dianhydro-5-*O*-[4-chloro-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-L-iditol; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

124. **(previously presented)** A compound selected from 1,1-dimethylethyl (3a*R*,6a*S*)-5-(hydroxymethyl)hexahydro cyclopenta[c] pyrrole-2(1*H*)-carboxylate; 1,1-dimethylethyl (3a*R*,6a*S*)-5-{[(methylsulfonyl)oxy]methyl}hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate; (3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl methanesulfonate; (3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; (3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl acetate; (3*S*,9a*S*)-3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; (3*R*,9a*S*)-3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; 3-(chloromethyl)hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazine; [(3*S*,8a*S*)-2-methyl-1-oxooctahydropyrrolo[1,2-*a*]pyrazin-3-yl]methyl methanesulfonate; (3*S*,8a*S*)-3-(hydroxymethyl)-2-methylhexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-(hydroxymethyl)-hexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-3-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl) hexahydropyrrolo[1,2-*a*]pyrazin-1(2*H*)-one; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl methanesulfonate; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethanol; (3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazin-3-ylmethyl acetate; (3*S*,8a*R*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; (3*R*,8a*S*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; (3*R*,8a*R*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; and (3*S*,8a*S*)-3-(chloromethyl)hexahydro-1*H*-pyrrolo[2,1-*c*][1,4]oxazine; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

125. **(previously presented)** A pharmaceutical composition comprising a compound of Formula I or Ia and a pharmaceutically acceptable carrier.

126. **(previously presented)** A method of modulating the *in vivo* activity of a kinase selected from ephrin and EGFR, the method comprising administering to a subject an

effective amount of a compound of Formula I or Ia optionally together with a pharmaceutically acceptable carrier.

127. **(previously presented)** A method of treating a disease or a disorder associated with abnormal cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound of Formula I or Ia optionally together with a pharmaceutically acceptable carrier.

128. **(previously presented)** The method of Claim 127 where the disease is cancer.

129. **(previously presented)** The method of Claim 128 where the cancer is modulated by one or more kinases selected from ephrin, KDR, Flt-1, EGFR, and ErbB2.

130. **(previously presented)** The method of Claim 127 where the cancer is selected from non-small cell lung cancer, glioblastoma, pancreatic cancer, cancer of the nervous system, cancer of the large bowel, multiple myeloma, undifferentiated small cell bronchogenic carcinoma, gastrointestinal cancer, esophageal cancer, malignant melanoma, neuroblastoma, osteosarcoma, ovarian cancer, endometrial cancer, cervical cancer, bladder cancer, urethral cancer, and prostate cancer.

131. **(previously presented)** The method of Claim 127 where the cancer is selected from non-small cell lung cancer, glioblastoma, pancreatic cancer, cancer of the nervous system, cancer of the large bowel, neuroblastoma, and gastrointestinal cancer.

132. **(previously presented)** The method of Claim 127 where the cancer is selected from ovarian cancer, cervical cancer, bladder cancer, esophageal cancer, and malignant melanoma, and prostate cancer.

133. **(previously presented)** The method of Claim 128 where the cancer is non-small cell lung cancer.

134. **(previously presented)** The method of Claim 128 where the cancer is glioblastoma.

135. **(previously presented)** The method of Claim 130 where the gastrointestinal cancer is stomach cancer.

136. **(previously presented)** The method of Claim 127 where the disease is selected from ischemic coronary artery disease, diabetic retinopathy, psoriasis and rheumatoid arthritis.

137. **(new)** The compound of Claim 68 selected from

N-(3,4-dichlorophenyl)-6-(methyloxy)-7-{[(8a*R*)-tetrahydro-1*H*-[1,3]thiazolo[4,3-*c*][1,4]oxazin-6-ylmethyl]oxy}quinazolin-4-amine;
3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-1,2-*O*-(1-methylethylidene)-beta-L-xylo-hexofuranose;
3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-1,2-*O*-(1-methylethylidene)-β-D-idofuranose;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-[(octahydro-2*H*-quinolizin-3-ylmethyl)oxy]quinazolin-4-amine;
N-(4-bromo-3-chlorophenyl)-7-{[(3a'*S*,4*R*,6'*S*,6a'*R*)-2,2-dimethyltetrahydrospiro[1,3-dioxolane-4,3'-furo[3,2-*b*]furan]-6'-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-(methylsulfonyl)-L-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-(methylsulfonyl)-D-glucitol;
2-amino-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol;
2-amino-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-(6-(methyloxy)-4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}quinazolin-7-yl)-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-(6-(methyloxy)-4-{[4-(4-methylpiperazin-1-yl)phenyl]amino}quinazolin-7-yl)-L-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-{[2,3-dichloro-4-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-{[3,4-dichloro-2-(4-methylpiperazin-1-yl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-fluoro-L-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

138. **(new)** The Compound of Claim 81 selected from

N-(4-bromo-2,3-dichlorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*S*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;

N-(3,4-dichloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*R*,9a*S*)-hexahydro-1*H*-[1,4]oxazino[3,4-*c*][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

139. **(new)** The Compound of Claim 81 selected from

N-(3,4-dichlorophenyl)-7-{[(3*R*,8a*R*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3*S*,8a*R*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3*R*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-{[(3*S*,8a*S*)-hexahydro-1*H*-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl]oxy}-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

140. **(new)** The Compound of Claim 85 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3a*R*,6a*S*)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3a*R*,6a*S*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,6a*S*)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

141. **(new)** The Compound of Claim 85 selected from

N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta-[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3a*R*,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]oxy}-6-(methyloxy)quinazolin-4-amine; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

142. **(new)** The Compound of Claim 87 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3a*R*,5r,6a*S*)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;

ethyl (3a*R*,5r,6a*S*)-5-[({4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;

N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine;
1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1*H*)-carboxylate; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

143. **(new)** The Compound of Claim 85 selected from

N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-(1-methylethyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
7-({[(3a*R*,5r,6a*S*)-2-acetyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-*N*-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine;
ethyl (3a*R*,5r,6a*S*)-5-[({4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}oxy)methyl]hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3-chloro-2,4-difluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta-[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;

N-(4,5-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-5-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-2,3-dichlorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-ethyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-({[(3a*R*,5r,6a*S*)-2-(2-methylpropyl)octahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)quinazolin-4-amine; and
1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate;
N-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine
1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1*H*)-carboxylate; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

144. **(new)** The Compound of Claim 143 selected from *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; *N*-(4-bromo-3-chloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclo-penta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5s,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine; and optionally as a pharmaceutically acceptable salt or hydrate thereof.

145. **(new)** The pharmaceutical composition of Claim 144.

146. **(new)** The Compound of Claim 143 selected from 1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyl-oxy)quinazolin-7-yl]oxy}methyl)hexahydrocyclopenta[c]pyrrole-2(1*H*)-carboxylate; N-(4-bromo-3-chloro-2-fluorophenyl)-6-(methyloxy)-7-{[(3aR,5r,6aS)-octahydrocyclopenta[c]pyrrol-5-ylmethyl]oxy}quinazolin-4-amine; *N*-(3,4-dichloro-2-fluorophenyl)-6-(methyloxy)-7-{[[(3a*R*,5r,6a*S*)-octahydrocyclopenta[c]pyrrol-5-yl]methyl]oxy}quinazolin-4-amine; 1,1-dimethylethyl (3a*R*,6a*S*)-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl) hexahydrocyclopenta-[c]pyrrole-2(1*H*)-carboxylate; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

147. **(new)** The Compound of Claim 144 named *N*-(3,4-dichloro-2-fluorophenyl)-7-({[(3a*R*,5r,6a*S*)-2-methyloctahydrocyclopenta[c]pyrrol-5-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine optionally as a pharmaceutically acceptable salt or hydrate thereof.

148. **(new)** The pharmaceutical composition of Claim 147.

149. **(new)** The Compound of Claim 96 selected from

(3*S*,9a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2*H*-pyrido[1,2-a]pyrazin-1(6*H*)-one;
(3*S*,9a*R*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydro-2*H*-pyrido[1,2-a]pyrazin-1(6*H*)-one;
(3*S*,8a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one;
(3*S*,8a*R*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one;
(3*S*,8a*S*)-3-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)hexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one;
(3*S*,8a*S*)-3-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2*H*)-one; and

a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

150. **(new)** The Compound of Claim 99 selected from

N-(3,4-dichlorophenyl)-7-({2-[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)amino]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-[(2-{[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}ethyl)oxy]-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)ethyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({2-[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)methyl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-({[(3-*endo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]methyl}oxy)-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
N-(3,4-dichlorophenyl)-7-{[(3-*exo*)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-6-(methyloxy)quinazolin-4-amine;
7-{[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-ylmethyl]oxy}-*N*-(3,4-dichlorophenyl)-6-(methyloxy)quinazolin-4-amine;
1,1-dimethylethyl (3-*endo*)-3-(2-{[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}ethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate; and
7-({2-[(3-*endo*)-8-azabicyclo[3.2.1]oct-3-yl]ethyl}oxy)-*N*-(3,4-dichlorophenyl)-6-(methyloxy) quinazolin-4-amine; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

151. **(new)** The Compound of Claim 117 selected from

1,4:3,6-dianhydro-5-*O*-[4-[(2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-[(2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-[(4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(2-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

152. **(new)** The Compound of Claim 120 selected from

1,4:3,6-dianhydro-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-deoxy-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-*O*-methyl-D-threo-hexitol;

1,4:3,6-dianhydro-5-deoxy-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-methyl-5-*O*-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-sorbose ethylene glycol acetal;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-(difluoromethyl)-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-ethyl-L-iditol;

1,4:3,6-dianhydro-2-*O*-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylo-hexitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-D-glucitol;
methyl 3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-alpha-L-idofuranoside;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xylo-hexitol;
methyl 3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-beta-L-idofuranoside;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{6-(methyloxy)-4-[(2,3,4-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(2-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(2-bromo-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-{[4-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,3-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;

1,4:3,6-dianhydro-5-*O*-[4-[(5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(3,5-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-chloro-4-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-2-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{6-(methyloxy)-4-[(2,4,5-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{6-(methyloxy)-4-[(2,4,6-trifluorophenyl)amino]quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-({4-[(4-chlorophenyl)oxy]-3,5-difluorophenyl}amino)-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chloro-5-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-{6-(methyloxy)-4-[(3,4,5-trichlorophenyl)amino]quinazolin-7-yl}-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-5-*O*-[4-[(4-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(3,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(2,5-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(2-bromo-4,6-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[2-chloro-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-{[2-fluoro-3-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[2-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[2-bromo-4-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-2-deoxy-2-fluoro-5-*O*-[4-{[4-fluoro-2-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[3-bromo-5-(trifluoromethyl)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-bromo-4-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(5-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;

1,4:3,6-dianhydro-2-deoxy-5-*O*-[4-[(3,5-dimethylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[5-chloro-2,4-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-{[4-chloro-2,5-bis(methyloxy)phenyl]amino}-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-fluoro-D-iditol;
1,4:3,6-dianhydro-5-*O*-{4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-deoxy-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-5-C-[(methyloxy)methyl]-L-glucitol;
1,4:3,6-dianhydro-5-*O*-{4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-*O*-methyl-2-C-[(methyloxy)methyl]-D-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-D-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol;

1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-L-iditol;
2-*O*-acetyl-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
2-*O*-acetyl-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-D-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;

1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-5-C-(trifluoromethyl)-L-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-D-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol;
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

153. **(new)** The compound of Claim 152 selected from

1,4:3,6-dianhydro-5-({[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-xylo-hexitol;
1,4:3,6-dianhydro-5-({[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-deoxy-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-deoxy-2-({[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-5-*O*-methyl-D-threo-hexitol;
1,4:3,6-dianhydro-5-deoxy-5-({[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]oxy}methyl)-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-5-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;

1,4:3,6-dianhydro-2-*O*-[4-[(3,4-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-methyl-5-*O*-{6-(methyloxy)-4-[(2,3,4-trichlorophenyl)amino]quinazolin-7-yl}-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-2,3-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-sorbose ethylene glycol acetal;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2,4-difluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4,5-dichloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-(difluoromethyl)-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-ethyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3-bromo-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(3-chloro-2-methylphenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-D-xylo-hexitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-D-glucitol;

methyl 3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-alpha-L-idofuranoside;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-deoxy-5-methylidene-D-xylo-hexitol;
methyl 3,6-anhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-beta-L-idofuranoside;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-*O*-[4-[(3,4-dichlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-D-glucitol;
1,4:3,6-dianhydro-5-*O*-{4-[(3-chloro-2-fluorophenyl)amino]-6-(methyloxy)quinazolin-7-yl}-2-deoxy-2-fluoro-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-D-glucitol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-S-methyl-5-thio-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-morpholin-4-yl-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(4-methylpiperazin-1-yl)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-pyrrolidin-1-yl-L-iditol;
2-*O*-acetyl-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(methylsulfonyl)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(dimethylamino)-L-iditol;

1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-(diethylamino)-L-iditol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-piperidin-1-yl-L-iditol;
2-(acetylamino)-1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-L-iditol;
1,4:3,6-dianhydro-2-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-5-*O*-methyl-5-C-(trifluoromethyl)-D-glucitol;
1,4:3,6-dianhydro-5-*O*-[4-[(4-bromo-3-chlorophenyl)amino]-6-(methyloxy)quinazolin-7-yl]-2-deoxy-2-[(methylsulfonyl)amino]-L-iditol; and
a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof and optionally as a pharmaceutically acceptable salt or hydrate thereof.

154. **(new)** The Compound of Claim 124 selected from 1,1-dimethylethyl (3a*R*,6a*S*)-5-(hydroxymethyl)hexahydro cyclopenta[c] pyrrole-2(1*H*)-carboxylate; 1,1-dimethylethyl (3a*R*,6a*S*)-5-{[(methylsulfonyl)oxy]methyl}hexahydrocyclo-penta[c]pyrrole-2(1*H*)-carboxylate; and a single geometric isomer, stereoisomer, racemate, enantiomer, or diastereomer, thereof; and optionally as a pharmaceutically acceptable salt or hydrate thereof.